Serina Therapeutics (SER) announced that the first patient has been enrolled in the company’s Phase 1b registrational trial evaluating SER-252 in patients with advanced Parkinson’s disease. The Phase 1b registrational study is designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of SER-252 in patients with advanced Parkinson’s disease whose symptoms are inadequately controlled by current standard-of-care therapies. Serina remains on track to initiate dosing during the current quarter, consistent with previously disclosed guidance.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SER:
- Serina Therapeutics files to sell 7.72M shares of common stock for holders
- Morning News Wrap-Up: Thursday’s Biggest Stock Market Stories!
- This Is Why Serina Therapeutics Stock (SER) Rocketed Today
- Serina Therapeutics announces FDA clearance of SER-252 new drug application
- Serina Therapeutics receives NYSE deficiency notice on equity standards